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MIXED MESSAGES FROM PRECLINICAL DATA, 
GUIDELINES AND LABELLING
During the development of efavirenz, animal studies 
were conducted to assess its potential for birth defects. 
These primate data are likely to have made providers 
and regulators more aware of the potential risks with 
efavirenz. 
Malformations were observed in three out of 20 
monkey offspring from efavirenz-treated cynomolgus 
monkeys (versus none among 20 controls) in a 
developmental toxicity study. The monkeys were dosed 
throughout pregnancy with a dose resulting in plasma 
drug concentrations similar to those in humans given 
600 mg/day of efavirenz. Anencephaly and unilateral 
anophthalmia were observed in one monkey infant, 
micro-ophthalmia was observed in another, and cleft 
palate was seen in a third. As a consequence of this 
trial, efavirenz was classified as FDA category C.
In 2005, efavirenz was reclassified as FDA category 
D, indicating an established risk to the human 
fetus. This classification was based on three reports 
of myelomeningocele and one of Dandy-Walker 
syndrome to the Antiretroviral Pregnancy Register 
(APR).3 Each defect was reported retrospectively and 
therefore the relative risk cannot be calculated, as the 
denominator is unknown. Two of the reported cases 
of myelomeningocele (spina bifida) and the case of 
Dandy-Walker syndrome were reported in aborted 
fetuses. 
The low quality of evidence regarding the safety of 
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Clinical guidelines from the National Department of Health (DoH), South Africa, for prevention of mother-to-
child transmission (PMTCT), revised in 2010, recommend that HIV-positive pregnant women with a CD4 count 
of 350 cells/µl or less commence lifelong antiretroviral therapy (ART).1
DoH guidance for women initiating ART in pregnancy in the public sector – on which the overwhelming majority 
of HIV-positive South Africans rely for their care – recommends they receive nevirapine with tenofovir and 
lamivudine or emtricitabine at any stage of gestation. In cases where a woman is already receiving ART with 
an efavirenz-based regimen, it is recommended that this should be substituted for nevirapine if she is still in 
the first trimester of pregnancy. Efavirenz is therefore contraindicated in pregnant women at any time during 
pregnancy; for those already receiving the drug, it is only switched in the first trimester.
The concern about the use of efavirenz in pregnancy dates back to preclinical studies. It is the only antiretroviral 
with preclinical primate data and in turn has the strongest US Food and Drug Administration (FDA) category 
and the most scrutiny during pregnancy.2 The drug also has the most conflicting recommendations, both from 
guidelines and product labelling.
This article is a summary of what we know (and do not know) about using efavirenz in pregnancy. We argue 
that reconsideration of the risk and benefits of this evidence, which has informed South African guidance, is 
warranted.
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when making recommendations. This is particularly 
problematic for guidance in low- and middle-income 
countries such as South Africa, with few antiretroviral 
options and a public health approach. However, the APR 
provides some reassurance, as does a meta-analysis 
performed earlier this year.4
Both the registry and the meta-analysis suggest that a 
twofold increase in overall birth defects can be excluded, 
but some caution about the potential for increased 
neural tube defects remains because of the primate 
data. This, however, needs to be taken in the context 
of a low incidence of neural tube defects in the general 
population, which varies from country to country, and 
is in the range of 0.1% (South Africa is 0.36%). With 
current data it is only possible to exclude a potential 
tenfold or higher increase in risk, but as the authors 
of the meta-analysis described below suggest, even a 
fivefold increase would give an overall increase of less 
than 1%. It is also important to take into consideration 
that the neural tube closes by approximately 28 days’ 
gestation, so the potential risk is for women receiving the 
drug in the first trimester. Since pregnancies are seldom 
recognised by this stage, if there is a risk it would be in 
women who conceive while already taking efavirenz.   
This uncertainty has led to differences in interpretation 
when making recommendations. The World Health 
Organization (WHO) pregnancy guidelines recommend 
that efavirenz should not be initiated in the first 
trimester, but may be initiated in the second and third 
trimesters.5 The WHO adult guideline panel was unable 
to conclude from the evidence available whether there 
were benefits associated with the use of efavirenz 
compared with nevirapine in pregnant women after 
the first trimester and with higher or unknown CD4 
cell counts. However, they note that more than half the 
panel members preferred efavirenz in these situations.6 
US guidelines also state that efavirenz use can be 
considered after the first trimester. Other countries such 
as Zambia concur, although most European guidance is 
similar to South Africa.7-9
The British HIV Association (BHIVA) recommends: ‘Until 
more robust data are available it remains advisable to 
avoid efavirenz for women who may conceive.’10 These 
guidelines highlight two issues to consider for women 
who do conceive on efavirenz: the gestational age at 
presentation and the plasma half-life of efavirenz. They 
explain that, after stopping, it can take up to 3 weeks for 
efavirenz to clear from the plasma. Whether there is a 
key period during the first 6 weeks of fetal development 
when efavirenz affects central nervous system (CNS) 
development is unknown, as is the minimal teratogenic 
dose. They suggest ‘discontinuing efavirenz after neural 
tube closure will not influence the outcome’.
Furthermore, the prescribing information accompanying 
the drug is inconsistent. Bristol-Meyers Squibb (BMS) 
markets the originator efavirenz product (sold as Sustiva 
in the USA, Canada and some countries in the European 
Union). Their package insert states: ‘Fetal harm can 
occur when administered to a pregnant woman during 
the first trimester.’11
Merck Sharp and Dohme (MSD, who market efavirenz 
as Stocrin in South Africa and many other parts of the 
world) provides prescriber information for efavirenz 
that cautions against conception in patients already on 
efavirenz as opposed to the prescription of efavirenz 
in women already known to be pregnant, in line with 
the WHO and BHIVA recommendations focusing on 
very early gestational risk. Their package insert states 
that ‘pregnancy should be avoided in women receiving 
Stocrin®’.12
The generic manufacturer Aspen states: ‘The use of 
Aspen efavirenz during pregnancy is not recommended, 
as teratogenicity has been noted.’13 
THE ANTIRETROVIRAL PREGNANCY REGISTRY
The APR is an international registry started in 1989 to 
prospectively monitor potential birth defects in infants 
exposed to antiretrovirals in utero. It is one of the 
largest ongoing pregnancy registries in the world.
The objectives of the registry are to provide early warning 
of major teratogenicity, estimate the risk of birth 
defects, and collect supplementary data from animal, 
clinical and epidemiological studies. Data collection is 
through voluntary enrolment by those providing health 
care to pregnant women exposed to antiretrovirals, and 
in turn infant follow-up. The registry has summaries 
of relevant data for all registered antiretrovirals, and 
reports are updated twice a year.
The majority of reports (84.9%) are from the USA, with 
small numbers from elsewhere (e.g. 1.9% from South 
Africa). One of the current goals of the registry is to 
increase non-US reporting.
As of the last review, through January 2010, the 
prevalence of birth defects per 100 live births among 
women with first-trimester exposure to any antiretroviral 
was 2.8% (95% confidence interval (CI) 2.3 - 3.3). At 
this review there were 13 575 pregnancies enrolled in 
the registry, of which 11 867 (87.4%) reports, of which 
5 582 were first-trimester exposures, were used in the 
analysis. The overall rate reported is not significantly 
different from the prevalence of defects among women 
with initial exposure during the second and/or third 
trimester (2.5 per 100 live births). 
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Only 14 defects have been recorded in 546 infants born 
following first-trimester efavirenz exposure (2.6%, 
95% CI 1.4 - 4.3%). These include a single case of 
myelomeningocele and a single case of anophthalmia 
with severe oblique facial clefts and amniotic banding.
It is worth noting that since the incidence of 
myelomeningocele in the USA is 4.3 per 10 000 live 
births it would be expected that the number of cases 
observed in the prospectively reported register should 
be greater than this overall. 
META-ANALYSIS
Earlier this year, Ford et al. performed a systematic 
review of databases (to 2 February 2010) in order to 
identify observational cohorts reporting birth outcomes 
among infants exposed to maternal efavirenz during 
the first trimester of pregnancy. The findings from this 
analysis were published in AIDS in June 2010. Slightly 
modified data (to take in the updated APR report 
in January) were presented at IAS 2010.14 Besides 
birth defects of any kind the investigators looked at 
spontaneous abortions, termination of pregnancy, 
stillbirths and preterm delivery.
The investigators found that 16 studies met the 
inclusion criteria for the analysis. These included 11 
prospective and 5 retrospective cohorts. Nine studies 
were conducted in low and middle-income countries. 
Six were European and one primarily in the USA. Eight 
were reported in journal articles, and 6 as conference 
abstracts, one (MTCT-Plus) was an unpublished cohort 
and one the APR report.
This analysis found a pooled non-significant relative 
risk for efavirenz versus non-efavirenz of 0.85 (95% 
CI 0.60 - 1.21%, p=0.47). The investigators found low 
heterogeneity between studies (I2 = 0, 95% CI 0 - 
56.3%, p=0.85). The overall prevalence of birth defects 
was 2.9% (95% CI 2.1 - 4.0%), range 0 - 22.6% (95% 
CI 9.6 - 41%). This is similar to the ranges observed in 
the general population: 2.7%, 2.5% and 2.5 - 8% in the 
USA, France and South Africa, respectively. 
There was 1 infant out of 1 301 with a neural tube 
defect (myelomeningocele), giving a prevalence of 
0.08% (95% CI 0.02 - 0.43%). This is also similar 
to the ranges in the general population, but, as the 
investigators noted, the upper CI would give a higher 
prevalence, including than that of South Africa.
The relative risk between those exposed in the first 
trimester versus second/third trimester did not differ 
(RR=0.91, 95% CI 0.46 - 1.79%, p=0.79).
Stillbirth, spontaneous abortion and preterm delivery 
were also within the range of the general population.
Rates of termination of pregnancy ranged from 5.3% 
(95% CI 0.64 - 17.7%) to 33.7% (95% CI 23.7 - 44.9%). 
The investigators noted that one study in Soweto found 
a relative risk of termination 5.73 times higher (95% 
CI 1.45 - 22.75%, p=0.0017) among women receiving 
efavirenz compared with other antiretroviral drugs, 
highlighting a need for careful counselling of women 
and attitudes among providers. 
DATA FROM FRERE HOSPITAL
After the APR, the second largest data set included in 
the meta-analysis was from a large regional cohort in 
South Africa.15 This is also the largest study to date 
of efavirenz-based ART exposure from the second 
trimester onwards.
In this study Bera et al. evaluated data from the 
Efavirenz in Pregnancy Registry, which is prospective 
and based at the Frere Hospital in East London (a 
referral hospital for a large area of the Eastern Cape) 
and set up in January 2006. Women who conceived 
on efavirenz and presented in the first trimester were 
offered the choice of termination of pregnancy (to 20 
weeks’ gestation) or switched to another drug. Women 
who presented at 14 weeks or later and were eligible 
for ART were initiated on an efavirenz-based regimen.
Between 1 January 2006 and 31 December 2008, 744 
women were initiated on efavirenz-based regimens 
from the second trimester onward. Of these, 89 women 
were still pregnant at the time of evaluation and 32 
were lost to follow up.
During the same period, 220 women conceived while 
receiving efavirenz-based ART and 42 while receiving 
nevirapine-based ART. Of this group, 17 and 7 women 
were still pregnant and 8 and 2 women were lost 
to follow-up receiving efavirenz and nevirapine, 
respectively.
Women who had received efavirenz-based ART 
throughout the entire first trimester were classified 
as ‘complete first-trimester exposure’ and those who 
substituted efavirenz for another drug as ‘partial first-
trimester exposure’.
This analysis evaluated data from 851 women with 
pregnancy outcomes.
Of 623 women initiated on efavirenz in pregnancy, birth 
defects occurred in 16 live births, a prevalence of 2.6% 
(95% CI 1.5 - 4.2).  In 195 women who conceived while 
receiving efavirenz, birth defects occurred in 5/184 live 
births and 1/4 stillbirths, a prevalence of 3.3% (95% CI 
1.2 - 7.0). In this group, 93% received efavirenz-based 
ART for longer than 1 month before conception and all 
pregnancies were unintended.
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There were no significant differences in the prevalence 
of birth defects between the first- and second/third-
trimester exposure (prevalence ratio 1.27, 95% CI 
0.5 - 3.20, p=0.301). Neither were there differences 
between complete (4/131; 3.1%) and partial (2/53; 
3.8%) efavirenz exposure (prevalence ratio 0.81, 95% 
CI 0.15 - 4.29, p=0.556).
Worth noting is that there was also a birth defect in 1 
out of 33 live nevirapine-exposed infants, a prevalence 
of 3.0% (95% CI 0.1 - 15.8). The prevalence ratio of birth 
defects following conception on efavirenz compared 
with nevirapine was 1.08 (95% CI 0.13 - 8.65, p=0.69). 
However, the numbers of nevirapine exposures are far 
too small to draw any conclusions.
CONFLICTING FINDINGS IN RETROSPECTIVE 
STUDY PACTG 219/219C
Finally, a study of children enrolled in PACTG protocols 
219 and 219C – a multisite US cohort of children born 
to HIV-positive women set up to study the long term 
effects of in utero antiretroviral exposure – recently 
reported a higher prevalence of birth defects than 
found in other paediatric cohorts.16
This observation was difficult to interpret as exposed 
children were enrolled retrospectively up to 1 year of 
age (only prospective pregnancies are enrolled in the 
APR), and for reasons discussed below. 
Protocol 219 followed HIV-infected and uninfected 
children from May 1993 to August 2000. Children were 
eligible if their mothers were enrolled in a PACTG trial 
in pregnancy. In September 2000, protocol 219C was 
introduced, amending 219 to remove the eligibility 
criterion mandating enrolment in another PACTG 
trial. Birth defect data were recorded at study visits. 
Protocol 219 did not include a direct question about 
birth defects; 219C included this question.
The primary determinant was first-trimester exposure. 
Overall antiretroviral exposure, classes of antiretrovirals 
and specific antiretrovirals to which at least one child 
with a birth defect had first-trimester exposure were 
evaluated.
The reference group was children unexposed to the 
particular antiretroviral (or class of drug) during 
the first trimester, which included antiretroviral-
unexposed children, those only exposed in labour, those 
unexposed to the particular drug but exposed to other 
antiretrovirals, and children only exposed beyond the 
first trimester.
Clinicians were blinded to antiretroviral exposure and 
the outcome was presence of a birth defect within the 
first year of life.
A total of 117 children with at least one defect were 
reported out of the study population of 2 202 children. 
This gave an overall defect prevalence of 5.3% (95% CI 
4.4 - 6.3) and 4.7% (95% CI 3.8 - 5.6) if just the 103 
cases of major defects were included. The prevalence 
was 4.8% (95% CI 3.7 - 6.1) in children unexposed 
in the first trimester and 5.8% (95% CI 4.2 - 7.8) in 
exposed children. The majority of defects occurred 
in the heart and musculoskeletal system. A higher 
defect rate (5/32, 15.6%) was reported among children 
exposed to efavirenz in the first trimester compared 
with unexposed children, adjusted odds ratio 4.31 (95% 
CI, 1.56 - 11.86). The defects included 1 laryngomalacia, 
1 meningomyelocele, 1 hypospadias, 1 club foot, 1 
hypertonicity of extremities and 1 cleft palate.
There was also an association in children exposed to 
lopinavir/ritonavir, but when adjusted for first-trimester 
folate antagonist exposure, year of birth and perinatal 
study participation this did not persist (p=0.07), 
whereas the association with efavirenz continued.
It is difficult to know whether this study advances or 
confuses the field. Although based on 2 202 children, 
only a third (763) were exposed to any antiretroviral 
during the first trimester, compared with over 5 000 
in the APR. Consequently, with the exceptions of 
zidovudine, lamivudine and nelfinavir, few children 
were exposed to individual drugs, which accounts 
for the wide range of odds ratios and CIs. A similar 
phenomenon has been observed over the years in 
the APR with new antiretrovirals, which is followed 
by a gradual movement towards the mean as the 
denominator increases, suggesting that initial case 
notification may drive initial reports to the registry.
The findings also generally differ from the APR, in 
which only didanosine (4.5%, 95% CI 2.6 - 7.1%) has 
attracted attention owing to a small but persistent 
increase in risk of birth defects, while PIs in general, 
and lopinavir/ritonavir (1.7%, 95% CI 0.8 - 3.1%) in 
particular, have generally been found to be associated 
with no increase in risk.
As might be anticipated, folate antagonist exposure 
during the first trimester was associated with an 
increased prevalence of birth defects, although data 
were largely incomplete and the observation did not 
reach statistical significance. The observed confounding 
of this risk with lopinavir/ritonavir exposure is a 
reminder not to forget the obvious.
DISCUSSION
There is to date no evidence of an increase in the 
incidence of birth defects among infants exposed to 
efavirenz beyond the first trimester, and excluding the 
retrospective analysis, also no increase among infants 
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born to women receiving efavirenz in the first trimester. 
However, the authors of the meta-analysis note 
several limitations to the evidence base, including few 
studies reporting risk of bias or attempting to control 
for potential confounders, and most importantly the 
limited sample size.
They suggest that although these data should provide 
reassurance to providers regarding first-trimester 
exposure, the low incidence of neural tube defects in 
the general population means a larger sample size is 
still needed to rule out the increased risk of this specific 
defect.
They write: ‘The balance of risks and benefits of efavirenz 
in pregnancy merits some recalibration, particularly in 
resource-limited settings where drug formularies are 
limited, women of child bearing age represent the 
majority of those infected with HIV, coinfection with 
tuberculosis is frequent, and the risk of mortality for 
those who are eligible for ART is high.’
The approach in the new South African guidelines 
to use of efavirenz is far more cautious than that of 
the WHO. Whereas the WHO interpreted the risk as 
being limited to the first trimester, and allowed for 
the possibility that some risk may still exist only from 
first-trimester exposure in spite of the low-quality, 
conflicting evidence, the South African guidelines do 
not recommend its inclusion at all in pregnancy.
 
The South African guidelines rely on the 2004 approved 
package insert for Stocrin, which the Medicines Control 
Council (MCC) believes indicates an absolute bar on 
the use of efavirenz throughout pregnancy. However 
the MCC is open to revisiting this package insert 
should the applicant – in this case MSD – apply for 
an amendment and supply sufficient scientific data to 
justify the amendment.
Although it may be prudent to guide prescribers to 
avoid first-trimester exposure, there seems to be 
strong rationale to recommend the use of efavirenz in 
pregnancy in South Africa beyond this period, for the 
following reasons:
Simplification to maximise adherence. Efavirenz 
must be taken once a day whereas nevirapine is usually 
dosed twice a day with a 2-week induction phase. 
The other components of ART are dosed daily; use of 
nevirapine over efavirenz converts a once-daily to a 
twice-daily regimen.
Consistency with adult treatment regimens. Efavirenz 
plus tenofovir plus lamivudine or emtricitabine is 
recommended for almost all non-pregnant adults. 
Simplicity of monitoring. Efavirenz does not usually 
require additional blood tests to the overall regimen. 
Nevirapine requires baseline alanine aminotransferase 
(ALT), and liver function tests (LFT) if the baseline ALT is 
abnormal or if patients develop a rash, any significant 
mucocutaneous reactions, fever, jaundice or abdominal 
pain.
Reduction in incidence of toxicity:
n    Efavirenz compared with nevirapine is a safer drug 
with respect to adverse events, particularly for 
severe adverse events.
n    In a representative South African adult population, 
7.6% of patients who started ART with nevirapine 
had to stop the drug due to toxicity by 3 years, 
compared with 1.9% of those starting ART with 
efavirenz having to stop efavirenz due to toxicity. 
Most of the nevirapine substitutions were in the 
first 3 months of treatment.17
n    Nevirapine has been associated with an increased risk 
of toxicity in women with a CD4 count greater than 
250 cells/µl in early studies, and a box warning to 
this effect has been included. The WHO reviewed the 
literature and felt reassured to initiate nevirapine in 
women with high CD4 cell counts. Subsequent to this 
review an article representing over 10 000 patients 
treated with nevirapine-based ART suggested a high 
CD4 cell count in treatment-naïve patients to be a 
risk factor for nevirapine toxicity.18,19
Co-tuberculosis (TB) treatment:
n    Efavirenz has better blood levels when used 
with anti-TB treatment, specifically rifampicin, 
compared with nevirapine, resulting in slightly 
lower treatment failure.20
n    The first-line ART choice in the current South African 
guidelines for a patient with TB would be tenofovir 
plus lamivudine or emtricitabine plus efavirenz in 
all patients whether pregnant or not, at odds with 
the rationale for not recommending efavirenz in 
pregnant women who do not have tuberculosis.
n    Rash that occurs during co-administration may 
be due to the TB drugs or nevirapine, and it may 
occasionally be difficult to determine which to 
stop.
Availability of fixed-dose combinations (FDCs):
n    Efavirenz is included in a couple of FDCs that 
are pending registration in South Africa – these 
are tenofovir plus lamivudine plus efavirenz, and 
tenofovir plus emtricitabine plus efavirenz. The FDA 
has already tentatively approved such products 
(tentative only in that patent protection currently 
prevents them from being marketed in the USA).
n    FDCs facilitate adherence and simplify the taking of 
treatment. They take up less space, with transport 
and storage savings. 
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It is instructive that in the USA, in 2009, among pregnant 
women receiving NNRTI-based ART, over four times as 
many receive efavirenz compared with nevirapine.21 In 
a UK cohort, nearly 20% of women receiving an NNRTI 
regimen before conception received efavirenz.22
Bera et al. above15 note that all the pregnancies in the 
women conceiving on efavirenz in their cohort were 
unintended, and an investigation into the correct 
application of guidelines in Johannesburg revealed that 
the majority (77 - 90%) of women were incorrectly 
assigned to efavirenz with respect to contraception 
use, and 39% were either trying to conceive or planned 
to do so in the next year.23
CONCLUSION
In short, the recommendation for nevirapine in 
pregnancy, based on poor data concerning the first 
trimester and without rationale beyond the first 
trimester, will result in women being exposed to a 
more toxic and more complicated regimen, which has 
significant additional operational challenges and differs 
from the otherwise very uniform approach to first-line 
ART provision to adults in the national programme. If 
indeed there is a concern about neural tube defects, 
the appropriate guideline response should be to 
focus on the avoidance of conception in women on 
efavirenz in line with the WHO recommendations and 
the prescriber information that accompanies efavirenz 
when distributed as Stocrin.
This real risk to maternal health and in turn child health 
must be weighed up against the theoretical risk of fetal 
toxicity. We believe that the decision to uniformly use 
nevirapine in pregnancy is a poor one in the absence 
of better data, and should be reviewed by the MCC and 
the Department of Health.
Thanks to Graham Taylor and Karen Beckerman.
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